SeaStar Medical Holding Corporation
ICUHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. With a market capitalization of $13.1M, it sits in micro-cap territory. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Market Cap
$13.1M
Beta
-1.03
P/E (TTM)
—
P/E (Fwd)
-1.16
EPS (TTM)
$-1.89
EPS (Fwd)
$-2.57
ROE
-356.9%
ROA
-102.7%
Cash
$7.0M
Total Debt
$134,000
Free CF
-$9.1M
52W Change
-65.9%
Annual Financials
Cash vs Debt
Where ICU stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ICU finished 15.54% below its 150-day moving average ($3.41) and 11.93% below its 200-day moving average ($3.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICU overbought or oversold?
At the September 3, 2026 close, ICU's RSI(14) was 33.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $7.0M in cash and $134K in debt, ICU maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$9.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -356.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, SeaStar Medical Holding Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ICU.